Current status and future perspectives on the etiology of esophageal adenocarcinoma

Frontiers in Oncology

Volumn 2, Issue FEB, 2012, Pages

  Thrift, Aaron P ^a,b   Pandeya, Nirmala ^a   Whiteman, David C ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Barrett's esophagus; Epidemiology; Esophageal adenocarcinoma; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; BENZODIAZEPINE; CALCIUM CHANNEL BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

AGE; BARRETT ESOPHAGUS; CANCER EPIDEMIOLOGY; CANCER RISK; DIET; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ETHNICITY; FRUIT; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; META ANALYSIS (TOPIC); OBESITY; RISK FACTOR; SHORT SURVEY; SMOKING; VEGETABLE;

EID: 84879433956     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2012.00011     Document Type: Short Survey

References (106)

1. Abrams, J. A., Sharaiha, R. Z., Gonsalves, L., Lightdale, C. J., and Neugut, A. I. (2011). Dating the rise of esophageal adenocarcinoma: analysis of Connecticut Tumor Registry data, 1940-2007. Cancer Epidemiol. Biomarkers Prev. 20, 183-186.
2. American Cancer Society. (2011). Cancer Facts and Figures 2011. Atlanta, GA: American Cancer Society.
3. Anderson, L. A., Cantwell, M. M., Watson, R. G. P., Johnston, B. T., Murphy, S. J., Ferguson, H. R., McGuigan, J., Comber, H., Reynolds, J. V., and Murray, L. J. (2009). The association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Gastroenterology 136, 799-805.
4. Anderson, L. A., Johnston, B. T., Watson, R. G. P., Murphy, S. J., Ferguson, H. R., Comber, H., McGuigan, J., Reynolds, J. V., and Murray, L. J. (2006). Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res. 66, 4975-4982.
5. Anderson, L. A., Murphy, S. J., Johnston, B. T., Watson, R. G. P., Ferguson, H. R., Bamford, K. B., Ghazy, A., McCarron, P., McGuigan, J., Reynolds, J. V., Comber, H., and Murray, L. J. (2008). Relationship between Helicobacter pylori infection and gastric atrophy and the stages of the oesophageal inflammation, metaplasia, adenocarcinoma sequence: results from the FINBAR case-control study. Gut 57, 734-739.
6. Anderson, L. A., Watson, R. G., Murphy, S. J., Johnston, B. T., Comber, H., Mc Guigan, J., Reynolds, J. V., and Murray, L. J. (2007). Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J. Gastroenterol. 13, 1585-1594.
7. Atherton, J. C., and Blaser, M. J. (2009). Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J. Clin. Invest. 119, 2475-2487.
8. Blaser, M. J., and Atherton, J. C. (2004). Helicobacter pylori persistence: biology and disease. J. Clin. Invest. 113, 321-333.
9. Bosetti, C., Levi, F., Ferlay, J., Garavello, W., Lucchini, F., Bertuccio, P., Negri, E., and La Vecchia, C. (2008). Trends in oesophageal cancer incidence and mortality in Europe. Int. J. Cancer 122, 1118-1129.
10. Botterweck, A. A., Schouten, L. J., Volovics, A., Dorant, E., and van den Brandt, P. A. (2000). Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int. J. Epidemiol. 29, 645-654.
11. Brown, L. M., Devesa, S. S., and Chow, W. H. (2008). Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J. Natl. Cancer Inst. 100, 1184-1187.
12. Cameron, A. J., Zinsmeister, A. R., Ballard, D. J., and Carney, J. A. (1990). Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 99, 918-922.
13. Chow, W. H., Finkle, W. D., McLaughlin, J. K., Frankl, H., Ziel, H. K., and Fraumeni, J. F. (1995). The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 274, 474-477.
14. Clemons, N. J., McColl, K. E., and Fitzgerald, R. C. (2007). Nitric oxide and acid induce double-strand DNA breaks in Barrett's esophagus carcinogenesis via distinct mechanisms. Gastroenterology 133, 1198-1209.
15. Coleman, H. G., Bhat, S., Johnston, B. T., McManus, D., Gavin, A. T., and Murray, L. J. (2012). Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett's esophagus. Gastroenterology 42, 233-240.
16. Considine, R. V. (2001). Regulation of leptin production. Rev. Endocr. Metab. Disord. 2, 357-363.
17. Cook, M. B., Chow, W. H., and Devesa, S. S. (2009). Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br. J. Cancer 101, 855-859.
18. Cook, M. B., Kamangar, F., Whiteman, D. C., Freedman, N. D., Gammon, M. D., Bernstein, L., Brown, L. M., Risch, H. A., Ye, W., Sharp, L., Pandeya, N., Webb, P. M., Wu, A. H., Ward, M. H., Giffen, C., Casson, A. G., Abnet, C. C., Murray, L. J., Corley, D. A., Nyren, O., Vaughan, T. L., and Chow, W. H. (2010). Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J. Natl. Cancer Inst. 102, 1344-1353.
19. Cook, M. B., Wild, C. P., and Forman, D. (2005). A systematic review and meta-analysis of the sex ratio for Barrett's esophagus, erosive reflux disease, and nonerosive reflux disease. Am. J. Epidemiol. 162, 1050-1061.
20. Cooper, B. T., Chapman, W., Neumann, C. S., and Gearty, J. C. (2006). Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Aliment. Pharmacol. Ther. 23, 727-733.
21. Corley, D. A., Kerlikowske, K., Verma, R., and Buffler, P. (2003). Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124, 47-56.
22. Corley, D. A., Kubo, A., Levin, T. R., Block, G., Habel, L., Rumore, G., Quesenberry, C., and Buffler, P. (2009). Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994-2006. Gut 58, 182-188.
23. Corley, D. A., Kubo, A., Levin, T. R., Block, G., Habel, L., Zhao, W., Leighton, P., Quesenberry, C., Rumore, G. J., and Buffler, P. A. (2007). Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 133, 34-41.
24. Corley, D. A., Kubo, A., Levin, T. R., Block, G., Habel, L., Zhao, W., Leighton, P., Rumore, G., Quesenberry, C., Buffler, P., and Parsonnet, J. (2008a). Helicobacter pylori infection and the risk of Barrett's oesophagus: a community-based study. Gut 57, 727-733.
25. Corley, D. A., Kubo, A., and Zhao, W. (2008b). Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol. Biomarkers Prev. 17, 352-358.
26. Corley, D. A., Levin, T. R., Habel, L. A., and Buffler, P. A. (2006). Barrett's esophagus and medications that relax the lower esophageal sphincter. Am. J. Gastroenterol. 101, 937-944.
27. Curado, M. P., Edwards, B., Shin, H. R., Storm, H., Ferlay, J., Heanue, M., and Boyle, P. (eds). (2007). Cancer Incidence in Five Continents, Vol. IX: IARC Scientific Publications No. 160 (Lyon: IARC).
28. Edelstein, Z. R., Farrow, D. C., Bronner, M. P., Rosen, S. N., and Vaughan, T. L. (2007). Central adiposity and risk of Barrett's esophagus. Gastroenterology 133, 403-411.
29. El-Serag, H. B., Aguirre, T. V., Davis, S., Kuebeler, M., Bhattacharyya, A., and Sampliner, R. E. (2004). Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am. J. Gastroenterol. 99, 1877-1883.
30. Falk, G. W. (2002). Barrett's esophagus. Gastroenterology 122, 1569-1591.
31. Farrow, D. C., Vaughan, T. L., Sweeney, C., Gammon, M. D., Chow, W. H., Risch, H. A., Stanford, J. L., Hansten, P. D., Mayne, S. T., Schoenberg, J. B., Rotterdam, H., Ahsan, H., West, A. B., Dubrow, R., Fraumeni, J. F., and Blot, W. J. (2000). Gastroesophageal reflux disease, use of H-2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control 11, 231-238.
32. Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., and Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893-2917.
33. Ford, A. C., Forman, D., Reynolds, P. D., Cooper, B. T., and Moayyedi, P. (2005). Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. Am. J. Epidemiol. 162, 454-460.
34. Fortuny, J., Johnson, C. C., Bohlke, K., Chow, W. H., Hart, G., Kucera, G., Mujumdar, U., Ownby, D., Wells, K., Yood, M. U., and Engel, L. S. (2007). Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers. Clin. Gastroenterol. Hepatol. 5, 1154-1159.
35. Freedman, N. D., Murray, L. J., Kamangar, F., Abnet, C. C., Cook, M. B., Nyrén, O., Ye, W., Wu, A. H., Bernstein, L., Brown, L. M., Ward, M. H., Pandeya, N., Green, A. C., Casson, A. G., Giffen, C., Risch, H. A., Gammon, M. D., Chow, W. H., Vaughan, T. L., Corley, D. A., and Whiteman, D. C. (2011). Alcohol intake and risk of esophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut 60, 1029-1037.
36. Hameeteman, W., Tytgat, G. N., Houthoff, H. J., and Vandentweel, J. G. (1989). Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 96, 1249-1256.
37. Hamilton, S. R., and Smith, R. R. (1987). The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus. Am. J. Clin. Pathol. 87, 301-312.
38. Hayeck, T. J., Kong, C. Y., Spechler, S. J., Gazelle, G. S., and Hur, C. (2010). The prevalence of Barrett's esophagus in the US: estimates from a simulation model confirmed by SEER data. Dis. Esophagus 23, 451-457.
39. Hillman, L. C., Chiragakis, L., Shadbolt, B., Kaye, G. L., and Clarke, A. C. (2004). Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med. J. Aust. 180, 387-391.
40. Hillman, L. C., Chiragakis, L., Shadbolt, B., Kaye, G. L., and Clarke, A. C. (2008). Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus. Aliment. Pharmacol. Ther. 27, 321-326.
41. Holmes, R. S., and Vaughan, T. L. (2007). Epidemiology and pathogenesis of esophageal cancer. Semin. Radiat. Oncol. 17, 2-9.
42. Huang, J. Q., Sridhar, S., Chen, Y., and Hunt, R. H. (1998). Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 114, 1169-1179.
43. Hvid-Jensen, F., Pedersen, L., Drewes, A. A., Sørensen, H. T., and Funch-Jensen, P. (2011). Incidence of adenocarcinoma among patients with Barrett's esophagus. N. Engl. J. Med. 365, 1375-1383.
44. Ibiebele, T. I., Hughes, M. C., O'Rourke, P., Webb, P. M., Whiteman, D. C., and Australian Cancer Study. (2008). Cancers of the esophagus and carbonated beverage consumption: a population-based case-control study. Cancer Causes Control 19, 577-584.
45. Ibiebele, T. I., Taylor, A. R., Whiteman, D. C., and van der Pols, J. C. (2010). Eating habits and risk of esophageal cancers: a population-based case-control study. Cancer Causes Control 21, 1475-1484.
46. Islami, F., Boffetta, P., Ren, J. S., Pedoeim, L., Khatib, D., and Kamangar, F. (2009). High-temperature beverages and foods and esophageal cancer risk: a systematic review. Int. J. Cancer 125, 491-524.
47. Islami, F., and Kamangar, F. (2008). Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev. Res. (Phila.) 1, 329-338.
48. Jankowski, J., and Moayyedi, P. (2004). Re: cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J. Natl. Cancer Inst. 96, 885-887.
49. Johansson, J., Hakansson, H. O., Mellblom, L., Kempas, A., Johansson, K. E., Granath, F., and Nyren, O. (2007). Risk factors for Barrett's oesophagus: a population-based approach. Scand. J. Gastroenterol. 42, 148-156.
50. Kamat, P., Wen, S. J., Morris, J., and Anandasabapathy, S. (2009). Exploring the association between elevated body mass index and Barrett's esophagus: a systematic review and meta-analysis. Ann. Thorac. Surg. 87, 655-662.
51. Kendall, B. J., Macdonald, G. A., Hayward, N. K., Prins, J. B., Brown, I., Walker, N., Pandeya, N., Green, A. C., Webb, P. M., Whiteman, D. C., and Study of Digestive Health. (2008). Leptin and the risk of Barrett's oesophagus. Gut 57, 448-454.
52. Kendall, B. J., and Whiteman, D. C. (2006). Temporal changes in the endoscopic frequency of new cases of Barrett's esophagus in an Australian health region. Am. J. Gastroenterol. 101, 1178-1182.
53. Kong, C. Y., Nattinger, K. J., Hayeck, T. J., Omer, Z. B., Wang, Y. C., Spechler, S. J., McMahon, P. M., Gazelle, G. S., and Hur, C. (2011). The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation model. Cancer Epidemiol. Biomarkers Prev. 20, 2450-2456.
54. Kubo, A., Block, G., Quesenberry, C. P., Buffler, P., and Corley, D. A. (2009). Effects of dietary fiber, fats, and meat intakes on the risk of Barrett's esophagus. Nutr. Cancer 61, 607-616.
55. Kubo, A., and Corley, D. A. (2007). Meta-analysis of antioxidant intake and the risk of esophageal and gastric cardia adenocarcinoma. Am. J. Gastroenterol. 102, 2323-2330.
56. Kubo, A., Levin, T. R., Block, G., Rumore, G., Quesenberry, C. P., Buffler, P., and Corley, D. A. (2009a). Cigarette smoking and the risk of Barrett's esophagus. Cancer Causes Control 20, 303-311.
57. Kubo, A., Levin, T. R., Block, G., Rumore, G. J., Quesenberry, C. P., Buffler, P., and Corley, D. A. (2009b). Alcohol types and sociodemographic characteristics as risk factors for Barrett's esophagus. Gastroenterology 136, 806-815.
58. Kubo, A., Levin, T. R., Block, G., Rumore, G. J., Quesenberry, C. P., Buffler, P., and Corley, D. A. (2008a). Dietary antioxidants, fruits, and vegetables and the risk of Barrett's esophagus. Am. J. Gastroenterol. 103, 1614-1623.
59. Kubo, A., Levin, T. R., Block, G., Rumore, G. J., Quesenberry, C. P., Buffler, P., and Corley, D. A. (2008b). Dietary patterns and the risk of Barrett's esophagus. Am. J. Epidemiol. 167, 839-846.
60. Ladanchuk, T. C., Johnston, B. T., Murray, L. J., Anderson, L. A., and FINBAR Study Group. (2010). Risk of Barrett's oesophagus, oesophageal adenocarcinoma and reflux oesophagitis and the use of nitrates and asthma medications. Scand. J. Gastroenterol. 45, 1397-1403.
61. Lagergren, J. (2005). Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut 54, i1-i5.
62. Lagergren, J., Bergstrom, R., Adami, H. O., and Nyren, O. (2000). Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann. Intern. Med. 133, 165-175.
63. Lagergren, J., Viklund, P., and Jansson, C. (2006). Carbonated soft drinks and risk of esophageal adenocarcinoma: a population-based case-control study. J. Natl. Cancer Inst. 98, 1158-1161.
64. Liao, L. M., Vaughan, T. L., Corley, D. A., Cook, M. B., Casson, A. G., Kamangar, F., Abnet, C. C., Risch, H. A., Giffen, C., Freedman, N. D., Chow, W. H., Sadeghi, S., Pandeya, N., Whiteman, D. C., Murray, L. J., Bernstein, L., Gammon, M. D., and Wu, A. H. (2012). Non-steroidal anti-inflammatory drug use reduces risk for adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology. doi: 10.1053/j.gastro.2011.11.019. [Epub ahead of print].
65. Mayne, S. T., Risch, H. A., Dubrow, R., Chow, W. H., Gammon, M. D., Vaughan, T. L., Borchardt, L., Schoenberg, J. B., Stanford, J. L., West, A. B., Rotterdam, H., Blot, W. J., and Fraumeni, J. F. (2006). Carbonated soft drink consumption and risk of esophageal adenocarcinoma. J. Natl. Cancer Inst. 98, 72-75.
66. Mayne, S. T., Risch, H. A., Dubrow, R., Chow, W. H., Gammon, M. D., Vaughan, T. L., Farrow, D. C., Schoenberg, J. B., Stanford, J. L., Ahsan, H., West, A. B., Rotterdam, H., Blot, W. J., and Fraumeni, J. F. (2001). Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol. Biomarkers Prev. 10, 1055-1062.
67. Merlo, L. M., Shah, N. A., Li, X., Blount, P. L., Vaughan, T. L., Reid, B. J., and Maley, C. C. (2010). A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev. Res. (Phila.) 3, 1388-1397.
68. Miros, M., Kerlin, P., and Walker, N. (1991). Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 32, 1441-1446.
69. Mulholland, H. G., Cantwell, M. M., Anderson, L. A., Johnston, B. T., Watson, R. G., Murphy, S. J., Ferguson, H. R., McGuigan, J., Reynolds, J. V., Comber, H., and Murray, L. J. (2009). Glycemic index, carbohydrate and fiber intakes and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Cancer Causes Control 20, 279-288.
70. Murphy, S. J., Anderson, L. A., Ferguson, H. R., Johnston, B. T., Watson, P. R., McGuigan, J., Comber, H., Reynolds, J. V., Murray, L. J., and Cantwell, M. M. (2010). Dietary antioxidant and mineral intake in humans is associated with reduced risk of esophageal adenocarcinoma but not reflux esophagitis or Barrett's esophagus. J. Nutr. 140, 1757-1763.
71. Musana, A. K., Resnick, J. M., Torbey, C. F., Mukesh, B. N., and Greenlee, R. T. (2008). Barrett's esophagus: incidence and prevalence estimates in a rural mid-western population. Am. J. Gastroenterol. 103, 516-524.
72. Ness-Jensen, E., Lindam, A. P., Lagergren, J., and Hveem, K. (2011). Changes in prevalence, incidence and spontaneous loss of gastro-oesophageal reflux symptoms: a prospective population-based cohort study, the HUNT study. Gut. doi: 10.1136/guyjnl-2011-300715. [Epub ahead of print].
73. Nguyen, D. M., El-Serag, H. B., Henderson, L., Stein, D., Bhattacharyya, A., and Sampliner, R. E. (2009). Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin. Gastroenterol. Hepatol. 7, 1299-1304.
74. Pohl, H., Sirovich, B., and Welch, H. G. (2010). Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol. Biomarkers Prev. 19, 1468-1470.
75. Pohl, H., and Welch, H. G. (2005). The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J. Natl. Cancer Inst. 97, 142-146.
76. Prach, A. T., MacDonald, T. A., Hopwood, D. A., and Johnston, D. A. (1997). Increasing incidence of Barrett's oesophagus: education, enthusiasm, or epidemiology? Lancet 350, 933.
77. Rabinovitch, P. S., Longton, G., Blount, P. L., Levine, D. S., and Reid, B. J. (2001). Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am. J. Gastroenterol. 96, 3071-3083.
78. Ranka, S., Gee, J. M., Johnson, I. T., Skinner, J., Hart, A. R., and Rhodes, M. (2006). Non-steroidal anti-inflammatory drugs, lower oesophageal sphincter-relaxing drugs and oesophageal cancer: a case-control study. Digestion 74, 109-115.
79. Ren, J. S., Freedman, N. D., Kamangar, F., Dawsey, S. M., Hollenbeck, A. R., Schatzkin, A., and Abnet, C. C. (2010). Tea, coffee, carbonated soft drinks and upper gastrointestinal tract cancer risk in a large United States prospective cohort study. Eur. J. Cancer 46, 1873-1881.
80. Rex, D. K., Cummings, O. W., Shaw, M., Cumings, M. D., Wong, R. K., Vasudeva, R. S., Dunne, D., Rahmani, E. Y., and Helper, D. J. (2003). Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 125, 1670-1677.
81. Risques, R. A., Vaughan, T. L., Li, X., Odze, R. D., Blount, P. L., Ayub, K., Gallaher, J. L., Reid, B. J., and Rabinovitch, P. S. (2007). Leukocyte telomere length predicts cancer risk in Barrett's esophagus. Cancer Epidemiol. Biomarkers Prev. 16, 2649-2655.
82. Rokkas, T., Pistiolas, D., Sechopoulos, P., Robotis, I., and Margantinis, G. (2007). Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin. Gastroenterol. Hepatol. 5, 1413-1417.
83. Ronkainen, J., Aro, P., Storskrubb, T., Johansson, S. E., Lind, T., Bolling-Sternevald, E., Vieth, M., Stolte, M., Talley, N. J., and Agreus, L. (2005). Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 129, 1825-1831.
84. Rubenstein, J. H., and Taylor, J. B. (2010). Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment. Pharmacol. Ther. 32, 1222-1227.
85. Sato, F., Jin, Z., Schulmann, K., Wang, J., Greenwald, B. D., Ito, T., Kan, T., Hamilton, J. P., Yang, J., Paun, B., David, S., Olaru, A., Cheng, Y., Mori, Y., Abraham, J. M., Yfantis, H. G., Wu, T. T., Fredericksen, M. B., Wang, K. K., Canto, M., Romero, Y., Feng, Z., and Meltzer, S. J. (2008). Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features. PLoS ONE 3, e1890. doi:10.1371/journal.pone.0001890
86. Shaheen, N. J., Crosby, M. A., Bozymski, E. M., and Sandler, R. S. (2000). Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 119, 333-338.
87. Sikkema, M., De Jonge, P. J., Steyerberg, E. W., and Kuipers, E. J. (2010). Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 8, 235-244.
88. Smith, K. J., O'Brien, S. M., Green, A. C., Webb, P. M., Whiteman, D. C., and Study of Digestive Health. (2009). Current and past smoking significantly increase risk for Barrett's esophagus. Clin. Gastroenterol. Hepatol. 7, 840-848.
89. Stavrou, E. P., McElroy, H. J., Baker, D. F., Smith, G., and Bishop, J. F. (2009). Adenocarcinoma of the oesophagus: incidence and survival rates in New South Wales, 1972-2005. Med. J. Aust. 191, 310-314.
90. Suerbaum, S., and Michetti, P. (2002). Medical progress: Helicobacter pylori infection. N. Engl. J. Med. 347, 1175-1186.
91. Thompson, O. M., Beresford, S. A., Kirk, E. A., Bronner, M. P., and Vaughan, T. L. (2010). Serum leptin and adiponectin levels and risk of Barrett's esophagus and intestinal metaplasia of the gastroesophageal junction. Obesity (Silver Spring) 18, 2204-2211.
92. Thompson, O. M., Beresford, S. A., Kirk, E. A., and Vaughan, T. L. (2009). Vegetable and fruit intakes and risk of Barrett's esophagus in men and women. Am. J. Clin. Nutr. 89, 890-896.
93. Thrift, A. P., Pandeya, N., Smith, K. J., Green, A. C., Hayward, N. K., Webb, P. M., and Whiteman, D. C. (2011a). Helicobacter pylori infection and the risks of Barrett's oesophagus: a population-based case-control study. Int. J. Cancer. doi: 10.1002/ijc.26242. [Epub ahead of print].
94. Thrift, A. P., Pandeya, N., Smith, K. J., Green, A. C., Webb, P. M., and Whiteman, D. C. (2011b). The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus. Aliment. Pharmacol. Ther. 34, 1235-1244.
95. Thrift, A. P., Pandeya, N., Smith, K. J., Mallitt, K. A., Green, A. C., Webb, P. M., and Whiteman, D. C. (2011c). Lifetime alcohol consumption and risk of Barrett's esophagus. Am. J. Gastroenterol. 106, 1220-1230.
96. van Soest, E. M., Dieleman, J. P., Siersema, P. D., Sturkenboom, M., and Kuipers, E. J. (2005). Increasing incidence of Barrett's oesophagus in the general population. Gut 54, 1062-1066.
97. Vaughan, T. L., Dong, L. M., Blount, P. L., Ayub, K., Odze, R. D., Sanchez, C. A., Rabinovitch, P. S., and Reid, B. J. (2005). Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol. 6, 945-952.
98. Vaughan, T. L., Farrow, D. C., Hansten, P. D., Chow, W. H., Gammon, M. D., Risch, H. A., Stanford, J. L., Schoenberg, J. B., Mayne, S. T., Rotterdam, H., Dubrow, R., Ahsan, H., West, A. B., Blot, W. J., and Fraumeni, J. F. (1998). Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. Cancer Epidemiol. Biomarkers Prev. 7, 749-756.
99. Vizcaino, A. P., Moreno, V., Lambert, R., and Parkin, D. M. (2002). Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int. J. Cancer 99, 860-868.
100. Whiteman, D. C., Parmar, P., Fahey, P., Moore, S. P., Stark, M., Zhao, Z. Z., Montgomery, G. W., Green, A. C., Hayward, N. K., Webb, P. M., and Australian Cancer Study. (2010). Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers. Gastroenterology 139, 73-83.
101. Whiteman, D. C., Sadeghi, S., Pandeya, N., Smithers, B. M., Gotley, D. C., Bain, C. J., Webb, P. M., Green, A. C., and Australian Cancer Study. (2008). Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 57, 173-180.
102. Williams, L. B., Fawcett, R. L., Waechter, A. S., Zhang, P. L., Kogon, B. E., Jones, R., Inman, M., Huse, J., and Considine, R. V. (2000). Leptin production in adipocytes from morbidly obese subjects: stimulation by dexamethasone, inhibition with troglitazone, and influence of gender. J. Clin. Endocrinol. Metab. 85, 2678-2684.
103. Wu, A. H., Tseng, C. C., Hankin, J., and Bernstein, L. (2007). Fiber intake and risk of adenocarcinomas of the esophagus and stomach. Cancer Causes Control 18, 713-722.
104. Yang, P. C., and Davis, S. (1988). Incidence of cancer of the esophagus in the United States by histologic type. Cancer 61, 612-617.
105. Yoshida, N. (2007). Inflammation and oxidative stress in gastroesophageal reflux disease. J. Clin. Biochem. Nutr. 40, 13-23.
106. Zagari, R. M., Fuccio, L., Wallander, M. A., Johansson, S., Fiocca, R., Casanova, S., Farahmand, B. Y., Winchester, C. C., Roda, E., and Bazzoli, F. (2008). Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut 57, 1354-1359.